Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01300156
Recruitment Status : Unknown
Verified February 2011 by National Cancer Center, Korea.
Recruitment status was:  Recruiting
First Posted : February 21, 2011
Last Update Posted : February 21, 2011
Asan Medical Center
Severance Hospital
Information provided by:
National Cancer Center, Korea

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).

Condition or disease Intervention/treatment Phase
Hodgkin's Lymphoma Drug: Oxaliplatin-based chemotherapy (ESHAOx) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)
Study Start Date : February 2011
Estimated Primary Completion Date : June 2013
Estimated Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: ESHAOx arm
Patients who are planned to be treated with ESHAOx chemotherapy
Drug: Oxaliplatin-based chemotherapy (ESHAOx)
  • Etoposide 40 mg/m2, D1-4
  • Methylprednisolone 500mg, D1-5
  • Cytarabine 2 g/m2, D5
  • Oxaliplatin 130 mg/m2, D1

Primary Outcome Measures :
  1. Overall Response rate to ESHAOx chemotherapy [ Time Frame: within 3 weeks after the completion of the treatment ]
    To evaluate response rate by Cheson criteria for malignant lymphoma after 3 and 6 cycles of treatment with ESHAOx regimen in patients with refractory or relapsed Hodgkin's lymphoma.

Secondary Outcome Measures :
  1. Overall survival, response duration, toxicity profiles [ Time Frame: up to 5 years after the completion of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously histologically confirmed Hodgkin's lymphoma
  • Failure to achieve a complete remission with the initial induction chemotherapy, or recurrent disease
  • Performance status (ECOG) ≤ 3
  • Age ≤ 75 years old
  • Number of prior chemotherapies: one or two regimens
  • At least one or more uni-dimensionally measurable lesion(s) defined as; ≥ 2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination
  • Adequate organ functions defined as; ANC > 1,500/ul, platelet > 75,000/ul, transaminases < 3 X upper normal values; bilirubin < 2 mg/dL
  • Written informed consent approved by institutional review board or ethic committee

Exclusion Criteria:

  • Previous high dose chemotherapy with autologous stem cell transplantation or allogeneic stem cell transplantation
  • Previous chemotherapies with ESHAP regimen
  • Any other malignancies within the past 5 years except skin basal cell carcinoma or carcinoma in situ of cervix
  • Other serious illness or medical conditions
  • Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
  • History of significant neurologic or psychiatric disorders including dementia or seizures
  • Active uncontrolled infection (viral, bacterial or fungal infection)
  • Other serious medical illnesses
  • Pregnancy or breast-feeding, women of childbearing potential not employing adequate contraception
  • Previous history of drug allergy to one of the drugs in the study regimen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01300156

Layout table for location contacts
Contact: Hyewon Lee, MD +82-31-920-1765

Layout table for location information
Korea, Republic of
National Cancer Center, Korea Recruiting
Goyang, Korea, Republic of
Contact: Hyewon Lee, MD    +82-31-920-1765   
Principal Investigator: Hyeon Seok Eom, MD, PhD         
Sponsors and Collaborators
National Cancer Center, Korea
Asan Medical Center
Severance Hospital
Layout table for investigator information
Principal Investigator: Hyeon Seok Eom, MD, PhD National Cancer Center, Korea

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hyeon-Seok Eom / MD, PhD, Natioinal Cancer Center, Korea Identifier: NCT01300156    
Other Study ID Numbers: NCCCTS-10-524
First Posted: February 21, 2011    Key Record Dates
Last Update Posted: February 21, 2011
Last Verified: February 2011
Keywords provided by National Cancer Center, Korea:
Hodgkin's disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Etoposide phosphate
Prednisolone hemisuccinate
Prednisolone phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents